Cargando…

Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration

We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feas...

Descripción completa

Detalles Bibliográficos
Autores principales: Lains, Ines, Mendez, Kevin M., Gil, João Q., Miller, John B., Kelly, Rachel S., Barreto, Patrícia, Kim, Ivana K., Vavvas, Demetrios G., Murta, Joaquim Neto, Liang, Liming, Silva, Rufino, Miller, Joan W., Lasky-Su, Jessica, Husain, Deeba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874679/
https://www.ncbi.nlm.nih.gov/pubmed/35207212
http://dx.doi.org/10.3390/jcm11040940
_version_ 1784657746626347008
author Lains, Ines
Mendez, Kevin M.
Gil, João Q.
Miller, John B.
Kelly, Rachel S.
Barreto, Patrícia
Kim, Ivana K.
Vavvas, Demetrios G.
Murta, Joaquim Neto
Liang, Liming
Silva, Rufino
Miller, Joan W.
Lasky-Su, Jessica
Husain, Deeba
author_facet Lains, Ines
Mendez, Kevin M.
Gil, João Q.
Miller, John B.
Kelly, Rachel S.
Barreto, Patrícia
Kim, Ivana K.
Vavvas, Demetrios G.
Murta, Joaquim Neto
Liang, Liming
Silva, Rufino
Miller, Joan W.
Lasky-Su, Jessica
Husain, Deeba
author_sort Lains, Ines
collection PubMed
description We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible alternative to plasma biomarkers. However, no studies have applied urinary mass spectrometry (MS) metabolomics to AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group. We included two prospectively designed, multicenter, cross-sectional study cohorts: Boston, US (n = 185) and Coimbra, Portugal (n = 299). We collected fasting urine samples, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography—Mass Spectrometry). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for gender, age, body mass index and use of AREDS supplementation. Results from both cohorts were then meta-analyzed. No significant differences in urine metabolites were seen when comparing patients with AMD and controls. When disease severity was considered as an outcome, six urinary metabolites differed significantly (p < 0.01). In particular, two of the metabolites identified have been previously shown by our group to also differ in the plasma of patients of AMD compared to controls and across severity stages. While there are fewer urinary metabolites associated with AMD than plasma metabolites, this study identified some differences across stages of disease that support previous work performed with plasma, thus highlighting the potential of these metabolites as future biomarkers for AMD.
format Online
Article
Text
id pubmed-8874679
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88746792022-02-26 Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration Lains, Ines Mendez, Kevin M. Gil, João Q. Miller, John B. Kelly, Rachel S. Barreto, Patrícia Kim, Ivana K. Vavvas, Demetrios G. Murta, Joaquim Neto Liang, Liming Silva, Rufino Miller, Joan W. Lasky-Su, Jessica Husain, Deeba J Clin Med Article We and others have shown that patients with different severity stages of age-related macular degeneration (AMD) have distinct plasma metabolomic profiles compared to controls. Urine is a biofluid that can be obtained non-invasively and, in other fields, urine metabolomics has been proposed as a feasible alternative to plasma biomarkers. However, no studies have applied urinary mass spectrometry (MS) metabolomics to AMD. This study aimed to assess urinary metabolomic profiles of patients with different stages of AMD and a control group. We included two prospectively designed, multicenter, cross-sectional study cohorts: Boston, US (n = 185) and Coimbra, Portugal (n = 299). We collected fasting urine samples, which were used for metabolomic profiling (Ultrahigh Performance Liquid chromatography—Mass Spectrometry). Multivariable logistic and ordinal logistic regression models were used for analysis, accounting for gender, age, body mass index and use of AREDS supplementation. Results from both cohorts were then meta-analyzed. No significant differences in urine metabolites were seen when comparing patients with AMD and controls. When disease severity was considered as an outcome, six urinary metabolites differed significantly (p < 0.01). In particular, two of the metabolites identified have been previously shown by our group to also differ in the plasma of patients of AMD compared to controls and across severity stages. While there are fewer urinary metabolites associated with AMD than plasma metabolites, this study identified some differences across stages of disease that support previous work performed with plasma, thus highlighting the potential of these metabolites as future biomarkers for AMD. MDPI 2022-02-11 /pmc/articles/PMC8874679/ /pubmed/35207212 http://dx.doi.org/10.3390/jcm11040940 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Lains, Ines
Mendez, Kevin M.
Gil, João Q.
Miller, John B.
Kelly, Rachel S.
Barreto, Patrícia
Kim, Ivana K.
Vavvas, Demetrios G.
Murta, Joaquim Neto
Liang, Liming
Silva, Rufino
Miller, Joan W.
Lasky-Su, Jessica
Husain, Deeba
Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title_full Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title_fullStr Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title_full_unstemmed Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title_short Urinary Mass Spectrometry Profiles in Age-Related Macular Degeneration
title_sort urinary mass spectrometry profiles in age-related macular degeneration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8874679/
https://www.ncbi.nlm.nih.gov/pubmed/35207212
http://dx.doi.org/10.3390/jcm11040940
work_keys_str_mv AT lainsines urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT mendezkevinm urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT giljoaoq urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT millerjohnb urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT kellyrachels urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT barretopatricia urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT kimivanak urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT vavvasdemetriosg urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT murtajoaquimneto urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT liangliming urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT silvarufino urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT millerjoanw urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT laskysujessica urinarymassspectrometryprofilesinagerelatedmaculardegeneration
AT husaindeeba urinarymassspectrometryprofilesinagerelatedmaculardegeneration